BioSpace News Archive

Business

Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update

Second Quarter Conference Call and Webcast Scheduled Today at 4:30 PM ET

August 3, 2018
·
15 min read
HitGen Launching Initiative to Discover New Medicines to Combat Tuberculosis and MalariaGrant Funding provided by the Bill & Melinda Gates Foundation to Use HitGen’s DNA-Encoded Library Technology

HitGen Ltd. announced today a three-year grant from the Bill & Melinda Gates Foundation.

August 3, 2018
·
1 min read
Genetown

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on August 1, 2018

SAGE Therapeutics announced that, on August 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 93,600 shares of its common stock to 16 new employees under Sage’s 2016 Inducement Equity Plan.

August 3, 2018
·
2 min read
Lone Star Bio

Nature Communications Publishes Studies Comparing Triumvira’s T Cell Antigen Coupler (TAC) Technology with CAR T Cell Therapy

Efficacy of Engineered T Cells can be Uncoupled from Toxicities Observed with CAR T Cell Therapy

August 3, 2018
·
3 min read
Policy

Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

AstraZeneca and Merck announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

August 3, 2018
·
7 min read
Business

Lannett Enters Licensing Agreement For Generic Concerta®, Methylphenidate Hydrochloride ER Tablets

Lannett Company, Inc. announced that it has entered into an exclusive perpetual licensing agreement with Andor Pharmaceuticals, LLC for Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths.

August 3, 2018
·
2 min read
Business

GNC Appoints Ken Martindale As Chairman

Bob Moran Becomes Lead Independent Director

August 3, 2018
·
3 min read
Policy

Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Patisiran

Positive Scientific Opinion Under Early Access to Medicines Scheme will Make Patisiran Treatment Available for UK hATTR Amyloidosis Patients Before Marketing Authorization

August 3, 2018
·
8 min read
Business

ViewRay Reports Second Quarter 2018 Financial Results

ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2018.

August 3, 2018
·
21 min read
Pharm Country

Regeneron Announces the 2018 Winners of the Regeneron Prize for Creative Innovation

Both young scientists are pursuing important research to further the understanding and treatment of neurological conditions

August 3, 2018
·
4 min read